Search results for Zenocutuzumab

Zenocutuzumab Biosimilar – Anti-ERBB2, ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1493

Description of Zenocutuzumab Biosimilar - Anti-ERBB2, ERBB3 mAb - Research Grade Introduction Zenocutuzumab Biosimilar, also known as Anti-ERBB2, ERBB3 mAb, is a monoclonal antibody that has been developed as a potential therapeutic agent for the treatment of various cancers. This biosimilar is a highly specific and potent inhibitor of the ERBB2 and ERBB3 receptors, which are known to play a crucial role in the growth and survival of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Zenocutuzumab Biosimilar in the field of cancer research. Structure of Zenocutuzumab Biosimilar Zenocutuzumab Biosimilar is a recombinant humanized monoclonal antibody that has been designed to target and block the activity of the ERBB2 and ERBB3 receptors. It is a biosimilar of the original Zenocutuzumab, which is a fully humanized monoclonal antibody. The biosimilar version has been developed using advanced biotechnological techniques, which ensure high levels of purity and consistency in its structure. The antibody is composed of two heavy chains and two light chains, which are linked by disulfide bonds. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL and CL1) and one variable domain (VL). The variable domains are responsible for binding to the specific target receptors, while the constant domains provide stability and effector functions. Mechanism of Action Zenocutuzumab Biosimilar exerts its anti- cancer activity by specifically binding to the extracellular domains of the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. This binding prevents the activation of downstream signaling pathways, which are responsible for promoting cell growth and survival. Additionally, the antibody also triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the destruction of cancer cells. Therapeutic Target: ERBB2 and ERBB3 Receptors The ERBB2 and ERBB3 receptors, also known as HER2 and HER3, respectively, belong to the epidermal growth factor receptor (EGFR) family. These receptors are often overexpressed in various types of cancer cells, including breast, lung, and gastric cancers. Overexpression of these receptors is associated with aggressive tumor growth, resistance to chemotherapy, and poor prognosis. Zenocutuzumab Biosimilar specifically targets these receptors, inhibiting their activity and preventing the growth and survival of cancer cells. This makes it a promising therapeutic agent for the treatment of HER2-positive and HER3-positive cancers. Potential Applications Zenocutuzumab Biosimilar has shown promising results in preclinical studies and is currently being evaluated in clinical trials for the treatment of various types of cancer. It has the potential to be used as a monotherapy or in combination with other anti- cancer agents. Some of the potential applications of Zenocutuzumab Biosimilar include: – Treatment of HER2-positive breast cancer: Zenocutuzumab Biosimilar has shown promising results in HER2-positive breast cancer, both as a single agent and in combination with other anti- cancer drugs. – Treatment of HER3-positive lung cancer: Zenocutuzumab Biosimilar has shown efficacy in preclinical studies against HER3-positive lung cancer, which is often resistant to traditional chemotherapy. – Treatment of HER2-positive gastric cancer: Zenocutuzumab Biosimilar has shown promising results in preclinical studies against HER2-positive gastric cancer, which is a highly aggressive and difficult-to-treat cancer. Conclusion In conclusion, Zenocutuzumab Biosimilar is a highly specific and potent monoclonal antibody that targets the ERBB2 and ERBB3 receptors, which are overexpressed in various types of cancer cells. Its unique mechanism

Zenocutuzumab, Abbexa, abx831452

Zenocutuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB2/ERBB3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Zenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).

Zenocutuzumab ELISA Kit, ProteoGenix, KPTX148

Description of Zenocutuzumab ELISA Kit Introduction to Zenocutuzumab ELISA Kit A Revolutionary Tool for Antibody Detection Zenocutuzumab ELISA Kit is a cutting-edge scientific tool used for the detection and measurement of Zenocutuzumab, a novel humanized monoclonal antibody. This kit is designed to provide accurate and reliable results for the quantification of Zenocutuzumab in various biological samples. In this article, we will discuss the structure, activity, and application of Zenocutuzumab ELISA Kit in detail. Structure of Zenocutuzumab ELISA Kit Zenocutuzumab ELISA Kit is composed of several key components that work together to detect and quantify Zenocutuzumab in a sample. The kit includes a microplate coated with a specific antigen that binds to Zenocutuzumab, a primary antibody conjugated with an enzyme, and a substrate solution that produces a colorimetric signal. The microplate is divided into wells, each of which can hold a specific volume of the sample and reagents. The kit also contains a wash buffer to remove any unbound substances and a stop solution to halt the enzymatic reaction. Activity of Zenocutuzumab ELISA Kit The activity of Zenocutuzumab ELISA Kit is based on the principle of enzyme-linked immunosorbent assay (ELISA). The microplate is coated with a specific antigen that captures Zenocutuzumab present in the sample. The primary antibody, which is conjugated with an enzyme, binds to the captured Zenocutuzumab. The amount of bound primary antibody is directly proportional to the concentration of Zenocutuzumab in the sample. After a series of washing steps, the substrate solution is added, which reacts with the enzyme to produce a color change. The intensity of the color is directly proportional to the amount of Zenocutuzumab present in the sample. The absorbance of the color is measured using a spectrophotometer, and the concentration of Zenocutuzumab in the sample is calculated using a standard curve. Application of Zenocutuzumab ELISA Kit Zenocutuzumab ELISA Kit is a powerful tool with a wide range of applications in the field of antibody detection and quantification. It is primarily used for the measurement of Zenocutuzumab levels in various biological samples, including serum, plasma, and cell culture supernatants. This kit can be used in research, drug development, and clinical settings. It is commonly used to monitor the pharmacokinetics of Zenocutuzumab in patients undergoing treatment. It can also be used to determine the presence of Zenocutuzumab in preclinical and clinical samples, which is crucial for the development and evaluation of this therapeutic antibody. Advantages of Zenocutuzumab ELISA Kit Zenocutuzumab ELISA Kit offers several advantages over traditional methods of antibody detection. It is a highly sensitive and specific assay, capable of detecting low levels of Zenocutuzumab in a sample. It is also a quick and easy-to-use method, with results available within a few hours. This kit also has a wide dynamic range, allowing for the measurement of both low and high concentrations of Zenocutuzumab. Moreover, it is a cost-effective option compared to other techniques, making it accessible to a wide range of researchers and clinicians. Conclusion Zenocutuzumab ELISA Kit is a state-of-the-art tool for the detection and quantification of Zenocutuzumab in various biological samples. Its unique structure and activity make it a reliable and accurate method for measuring this novel therapeutic antibody. With its wide range of applications and advantages, this kit is a valuable addition to the arsenal of tools used in antibody research and development.

Zenocutuzumab ELISA Kit, Abbexa, abx395037

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Zenocutuzumab ELISA Kit is a quantitative ELISA kit for detection of Zenocutuzumab.Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion-positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.

Zenocutuzumab Biosimilar - Research Grade, ichor.bio, ICH6013

Research Grade Zenocutuzumab (HY286096), abinScience, HY286096